Wisconsin scientists and start-up companies should continue to use human embryonic stem cells ? and their noncontroversial counterparts ? in ongoing research because they hold great promise for treating disease and injury, two panelists said Wednesday at the Early Stage Symposium.
Office of Strategic Communication